The Landscape
Gulf pharmaceutical manufacturers — particularly those serving SFDA in Saudi Arabia and MOHAP in the UAE — are building or expanding GMP-compliant manufacturing execution systems on accelerated timelines driven by Vision 2030 and national pharmaceutical self-sufficiency goals. The regulatory frameworks are stringent and evolving. Our teams deploy with Gulf regulatory requirements already mapped to the system architecture.
We build systems that are production-ready, compliant from architecture through deployment, and designed to pass the audit they will eventually face.
Our Approach
Compliance Coverage
Every system we deploy for Pharmaceuticals & Life Sciences in UAE & Gulf is FDA 21 CFR Part 11-compliant from architecture through deployment. FDA 21 CFR Part 11- and -HIPAA compliance is enforced automatically at every commit — not assessed after the fact.
Engagement Scope
Duration: 8–16 weeks
A focused team of 10–30 engineers deployed against a single Pharmaceuticals & Life Sciences platform in UAE & Gulf. FDA 21 CFR Part 11 + HIPAA-compliant architecture from day one. Fixed price, fixed output, no discovery phase.
Duration: 3–9 months
40–100 engineers running parallel workstreams across a Pharmaceuticals & Life Sciences transformation in UAE & Gulf. Multi-system compliance governance, integrated delivery management, and FDA 21 CFR Part 11 + HIPAA certification maintained across the entire program.
Duration: 6–18 months
100–250+ engineers owning the complete technology infrastructure for a Healthcare organization in UAE & Gulf. Full FDA 21 CFR Part 11 + HIPAA compliance across every system, every integration, every deployment — from the first commit to the final sign-off.